(NASDAQ: SCYX) Scynexis's forecast annual revenue growth rate of 158.97% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 121.12%, and it is also forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Scynexis's revenue in 2025 is $3,258,000.On average, 5 Wall Street analysts forecast SCYX's revenue for 2025 to be $188,829,934, with the lowest SCYX revenue forecast at $66,618,731, and the highest SCYX revenue forecast at $440,463,430. On average, 5 Wall Street analysts forecast SCYX's revenue for 2026 to be $1,952,318,728, with the lowest SCYX revenue forecast at $50,393,779, and the highest SCYX revenue forecast at $5,028,477,424.
In 2027, SCYX is forecast to generate $2,103,751,614 in revenue, with the lowest revenue forecast at $80,244,337 and the highest revenue forecast at $4,636,479,225.